Glenmark Pharma receives final approval for antiplatelet drug by USFDA
Category: #health  By Pankaj Singh  Date: 2019-05-28
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Glenmark Pharma receives final approval for antiplatelet drug by USFDA

Glenmark Pharmaceuticals, a U.S.-based pharmaceutical company, recently announced that it has received a final approval for antiplatelet agent Aspirin & extended-release Dipyridamole capsules from the U.S. Food and Drug Administration. Reportedly, the product approved is a generic version of Aggrenox capsules developed by Boehringer Ingelheim Pharmaceuticals.

For the record, Glenmark Pharmaceuticals Inc, USA is a global pharmaceutical company, established in 2003, as a North American subsidiary of Glenmark Pharmaceuticals. It is a leading generic organization in the U.S. The company is advancing scientific understanding with new therapies to improve human health and leverage the therapeutic potential of established drugs.

The company’s portfolio of products focuses on therapeutic areas such as dermatology, controlled substance, hormones and modified release products. It offers oral-solids, semi-solids, capsules and nitroglycerin sublingual tablets. Recently, the company received approval for Solifenacin Succinate tablets used for treatment of overactive bladder, from the U.S. health regulator. The product approved is a generic form of Vesicare tablets of Astellas Pharma US Inc.

The approval for the antiplatelet agent& extended-release Dipyridamole capsules comes almost on the heels of an announcement made previously in the same month that Glenmark Pharmaceuticals Inc, USA has received approval from USFDA for a generic version of Nexium, used to treat acid reflux.

As per reliable sources, the company has recently been granted a final approval by USFDA for Aspirin & Dipyridamole capsules, in strength of 25 milligrams/200 milligrams, the company claimed in a BSE filing. The company confirmed that the of 25 milligrams/200 milligrams market achieved sales of approximately $165.5 million in a period of one year, in March 2019.

The current portfolio of the company consists of 155 products, authorized for distribution in the U.S. and 58 ANDAs (Abbreviated New Drug Application) pending approvals with the USFDA. Glenmark Pharma’s shares closed at 0.30% higher at Rs 560.70 each, on the BSE, reports source.

Source credits: https://economictimes.indiatimes.com/markets/stocks/news/glenmark-pharma-gets-usfda-nod-for-antiplatelet-drug/articleshow/69513183.cms



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

The Bay collaborates with Rebelstork for gently used baby gear resale

The Bay collaborates with Rebelstork for gently used baby gear resale

By Pankaj Singh

Iconic retailer of Canada, The Bay has reportedly entered into a resale partnership with Rebelstork, a Canadian startup. Rebelstork is the first administered marketplace in North America for the resale of open box, qua...

Datopotamab Deruxtecan exhibits good tumor response in NSCLC patients

Datopotamab Deruxtecan exhibits good tumor response in NSCLC patients

By Pankaj Singh

According to new data for Dato-DXd (datopotamab deruxtecan), a DXd ADC (antibody drug conjugate) directed by TROP2 has reportedly showcased favorable tumor response rate in advanced NSCLC (non-small cell lung cancer) p...

Candy Club© reinforces retail commitment with new wholesale website

Candy Club© reinforces retail commitment with new wholesale website

By Pankaj Singh

Candy Club©, a growing candy brand that provides premium candy flavors with colorful packaging, has reportedly announced the launch of a new website for wholesale consumers to buy its products directly ...